Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Reemergence of PML in natalizumab-treated patients--new cases, same concerns.

× No keyword cloud information.

38 in total

1. Registries, research, and regrets: is the FDA's post-marketing REMS process not adequately protecting patients?

Authors: Norman J Kachuck
Journal: Ther Adv Neurol Disord Date: 2011-11 Impact factor: 6.570

Review 2. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies.

Authors: A Bellizzi; C Nardis; E Anzivino; D M Rodìo; D Fioriti; M Mischitelli; F Chiarini; V Pietropaolo
Journal: J Neurovirol Date: 2012-02 Impact factor: 2.643

3. Can primary immunodeficiencies help to provide insights into infectious risks of therapeutic antibodies?

Authors: László Maródi; Jean-Laurent Casanova
Journal: Nat Rev Immunol Date: 2010-05 Impact factor: 53.106

Review 4. Trafficking of immune cells in the central nervous system.

Authors: Emma H Wilson; Wolfgang Weninger; Christopher A Hunter
Journal: J Clin Invest Date: 2010-05-03 Impact factor: 14.808

5. Temporal data mining for adverse events following immunization in nationwide Danish healthcare databases.

Authors: Henrik Svanström; Torbjörn Callréus; Anders Hviid
Journal: Drug Saf Date: 2010-11-01 Impact factor: 5.606

6. Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximab.

Authors: Simone Giannecchini; Valeria Clausi; Alessandra Vultaggio; Lisa Macera; Fabrizio Maggi; Francesco Martelli; Alberta Azzi; Enrico Maggi; Andrea Matucci
Journal: J Neurovirol Date: 2012-01-27 Impact factor: 2.643

7. Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy.

Authors: Marco Tuccori; Daniele Focosi; Corrado Blandizzi; Matteo Pelosini; Sabrina Montagnani; Fabrizio Maggi; Mauro Pistello; Luca Antonioli; Matteo Fornai; Pasquale Pepe; Giuseppe Rossi; Mario Petrini
Journal: Oncologist Date: 2010-11-01

8. PML problems loom for Rituxan.

Authors: Malorye Allison
Journal: Nat Biotechnol Date: 2010-02 Impact factor: 54.908

9. Report on the current status of the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulation.

Authors: Alasdair M Breckenridge; Ross A Breckenridge; Carl C Peck
Journal: Br J Clin Pharmacol Date: 2019-07-10 Impact factor: 4.335

10. Heterogeneity among viral antigen-specific CD4+ T cells and their de novo recruitment during persistent polyomavirus infection.

Authors: Eugene Lin; Christopher C Kemball; Annette Hadley; Jarad J Wilson; Amelia R Hofstetter; Christopher D Pack; Aron E Lukacher
Journal: J Immunol Date: 2010-07-09 Impact factor: 5.422